TXMD — TherapeuticsMD Income Statement
0.000.00%
Last trade - 00:00- $20.14m
- $13.02m
- $1.76m
- 54
- 42
- 78
- 60
Annual income statement for TherapeuticsMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 64.9 | 2.57 | 70 | 1.3 | 1.76 |
| Cost of Revenue | |||||
| Gross Profit | 48.9 | 1.17 | 68.6 | 1.3 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 220 | 82.2 | 68.8 | 9.82 | 6.52 |
| Operating Profit | -156 | -79.6 | 1.19 | -8.52 | -4.76 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -184 | -79.3 | 1.07 | -7.74 | -2.34 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -184 | -79.3 | 1.07 | -7.7 | -2.31 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -184 | -172 | 112 | -10.3 | -2.18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -184 | -172 | 112 | -10.3 | -2.18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -33.1 | -9.96 | 16.4 | -0.737 | -0.129 |